Literature DB >> 19006186

Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis.

C Warren Olanow1, Jean-Michel Gracies, Christopher G Goetz, A Jon Stoessl, Thomas Freeman, Jeffrey H Kordower, James Godbold, Jose A Obeso.   

Abstract

The objective of this study is to assess dyskinesias in 34 Parkinson's disease patients randomized to receive bilateral fetal nigral transplantation with 4 donors per side (12), 1 donor per side (11), or placebo (11). Videotape recordings were performed at the baseline, 3, 6, 12, 18, and 24 month visits during the "practically defined off" (12 hours after last evening dopaminergic therapy) and "best on" (best response following morning dopaminergic therapy) states. Videotapes were analyzed in random order by a blinded investigator. Dyskinesias during "best on" (on-medication dyskinesia) were observed in all, but 1 patient at baseline, and in all patients at each subsequent visit. There were no differences between groups. No patient had dyskinesia at baseline in "practically-defined off" ("off-medication" dyskinesia). Following transplantation, off-medication dyskinesia was observed in 13 of 23 patients, but not in any patient in the placebo group (P = 0.019). There was no difference in dyskinesia score between patients in the 1 and 4 donor groups. On-medication dyskinesias were typically generalized and choreiform, whereas off-medication dyskinesias were usually repetitive, stereotypic movements in the lower extremities with residual Parkinsonism in other body regions. Off-medication dyskinesias are common following transplantation and may represent a prolonged form of diphasic dyskinesias. (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19006186     DOI: 10.1002/mds.22208

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  21 in total

Review 1.  Basic science in Parkinson's disease: its impact on clinical practice.

Authors:  Jörg B Schulz; Manfred Gerlach; Gabriele Gille; Wilfried Kuhn; Martina Müngersdorf; Peter Riederer; Martin Südmeyer; Albert Ludolph
Journal:  J Neurol       Date:  2011-05       Impact factor: 4.849

Review 2.  Molecular imaging of levodopa-induced dyskinesias.

Authors:  Flavia Niccolini; Lorenzo Rocchi; Marios Politis
Journal:  Cell Mol Life Sci       Date:  2015-02-15       Impact factor: 9.261

3.  Multiple system atrophy: current and future approaches to management.

Authors:  Olivier Flabeau; Wassilios G Meissner; François Tison
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

4.  Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient.

Authors:  Jeffrey H Kordower; Christopher G Goetz; Yaping Chu; Glenda M Halliday; Daniel A Nicholson; Timothy F Musial; David J Marmion; A Jon Stoessl; Vesna Sossi; Thomas B Freeman; C Warren Olanow
Journal:  Ann Neurol       Date:  2017-01-06       Impact factor: 10.422

5.  Anatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian Striatum.

Authors:  Kathy Steece-Collier; David J Rademacher; Katherine Soderstrom
Journal:  Basal Ganglia       Date:  2012-02-11

Review 6.  The immunological challenges of cell transplantation for the treatment of Parkinson's disease.

Authors:  Amanda L Piquet; Kala Venkiteswaran; Neena I Marupudi; Matthew Berk; Thyagarajan Subramanian
Journal:  Brain Res Bull       Date:  2012-04-11       Impact factor: 4.077

Review 7.  The origins of oxidant stress in Parkinson's disease and therapeutic strategies.

Authors:  Dalton James Surmeier; Jaime N Guzman; Javier Sanchez-Padilla; Joshua A Goldberg
Journal:  Antioxid Redox Signal       Date:  2010-12-15       Impact factor: 8.401

Review 8.  α-Synuclein and neuronal cell death.

Authors:  Toru Yasuda; Yasuto Nakata; Hideki Mochizuki
Journal:  Mol Neurobiol       Date:  2012-08-31       Impact factor: 5.590

9.  Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson's disease.

Authors:  Marios Politis
Journal:  BMC Med       Date:  2011-05-10       Impact factor: 8.775

10.  Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson's disease.

Authors:  J Guridi; R González-Redondo; J A Obeso
Journal:  Parkinsons Dis       Date:  2012-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.